# Coaxial wet-spun fibers loaded with essential oils for the treatment of chronic wounds

Catarina S. Miranda<sup>1</sup>, Elina Marinho<sup>1</sup>, Susana P. G. Costa<sup>2</sup>, Natália C. Homem<sup>3</sup> and Helena P. Felgueiras<sup>1,\*</sup>

<sup>1</sup>Centre for Textile Science and Technology (2C2T), University of Minho, Guimarães, Portugal


<sup>2</sup>Centre of Chemistry (CQ), University of Minho, Braga, Portugal

<sup>3</sup> Simoldes Plastics S.A., Oliveira de Azeméis, Portugal

### Introduction

Chronic wounds (CWs) can greatly impact the health and quality of the (a) patients' lives. The excessive use of antibiotics has led to a significant development of antibiotic-resistant microorganisms, making it crucial to think of alternative solutions. Considering these issues, a drug delivery system made of coaxial wet-spun fibers loaded with essential oils (EOs) was proposed. Coaxial structures were produced using the wet-spinning technique, in which polycaprolactone (PCL - a synthetic polymer with excellent mechanical properties and elastic behavior) solution was loaded at the core and mixed with three EOs – Clove Oil (CO), Cinnamon Leaf Oil (CLO) and Tea Tree Oil (TTO). The shell was composed of a blend of cellulose acetate (CA - a natural polymer which has been reported to offer good structural integrity) solution, mixed with polyethylene glycol (PEG - a synthetic polymer endowed with high elasticity and porosity), so pores could be opened in the outer layer, allowing for a sustained release of the EOs loaded at the fibers' core. Physical, chemical, thermal and biological characterizations were performed. Results confirmed the potential of the engineered coaxial wet-spun fibers for wound healing applications. Still, further characterization on the fibers is necessary, including cytocompatibility tests to assure non-toxic profiles of the fibers when in contact with fibroblasts and keratinocytes.


# **Fibers morphology**




### Wet-spinning


Technique based on a non-solvent-induced phase inversion process, including a polymeric solution extrusion into a coagulation bath composed by a poor solvent or a non-solvent/solvent mixture to form a coagulating filament that will solidify as a continuous polymeric fiber. Figure 1. Microscopic observations of (a) monolayered and (b) coaxial wet-spun fibers.

# **Release kinetics of EOs**





### **Coaxial wet-spun fibers**



#### Goal of Each Microfiber Component:


CA: generate porosity and maintain fibers' structural integrity
CO/CLO/TTO: antimicrobial activity
PEG: provide elasticity to the fibers
PCL: maintain fibers' structural integrity

#### \*MBC: Minimum Bactericidal Concentration

Produced fibers:

Figure 2. Cumulative release profile of EO-loaded wet-spun fibers. Data are reported as mean ± SD (n=3).

## **Antimicrobial activity**



**Figure 3**. Percentages of inhibition of (a) *S. aureus,* (b) *S. epidermidis,* (c) *E. coli* and (d) *P. aeruginosa* bacteria in contact with all wet-spun fibers incubated in PBS for 1, 2, 4, 6 and 24 h. Data are reported as mean ± SD (n=3).

# Conclusions

The potential of the engineered coaxial fibers to serve as controlled release platforms for CO/CLO/TTO was demonstrated, along with their antibacterial activity against *S. aureus, S. epidermidis, E. coli* and *P. aeruginosa*. Data confirmed the potential of this system to function as a stepwise, pH-triggered delivery platform, suitable for wound healing applications. With this investigation, a step further was taken in establishing wet-spun constructs for drug delivery in CW care.

- **CA hollow** (core: coagulation bath; shell: CA);
- CA-PEG hollow (core: coagulation bath; shell: CA combined with PEG);
- **PCL** (core: PCL; shell: coagulation bath);
- PCL-CO/CLO/TTO (core: PCL combined with CO/CLO/TTO; shell: coagulation bath);
- **PCL-CA** (core: PCL; shell: CA);
- **PCL-CO/CLO/TTO-CA** (core: PCL combined with CO/CLO/TTO; shell: CA);
- **PCL-CA-PEG** (core: PCL; shell: CA combined with PEG);
- PCL-CO/CLO/TTO-CA-PEG (core: PCL combined with CO/CLO/TTO; shell: CA combined with PEG).

# Acknowledgments

This work is financed by FEDER funds through COMPETE and by national funds through FCT via the projects POCI-01-0145-FEDER-028074 (PEPTEX) and UID/CTM/00264/2019. C.S.M. acknowledges FCT for the PhD grant with reference 2020.08547.BD.



The 9th International Electronic Conference on Medicinal Chemistry

01–30 November 2023 | Online